Medication leaflets

Active substance

Results for the substance turoctocog alfa pegol

5 results

About this active substance

Turoctocog alfa pegol is a modified form of recombinant factor VIII used for the treatment and prevention of bleeding episodes in patients with hemophilia A. By adding a polyethylene glycol (PEG) polymer, this medication has an extended duration of action, allowing for less frequent administration compared to conventional factor VIII.

Turoctocog alfa pegol is administered intravenously, with the dosage adjusted based on the severity of hemophilia, the patient's weight, and the treatment goal (prophylaxis or episodic treatment). It is used to reduce the frequency of bleeding episodes and prevent complications associated with hemophilia.

Common side effects include injection site reactions, headache, and fatigue. In rare cases, allergic reactions or the development of inhibitors to factor VIII may occur. Regular monitoring is essential to evaluate treatment efficacy and adjust the dosage if necessary.

Turoctocog alfa pegol represents an innovation in the treatment of hemophilia A, providing patients with an effective and convenient therapeutic option that improves their quality of life.